Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Use of Post-Induction Treatment in Mantle Cell Lymphoma (MCL) in Spain. Do All Young Fit Patients Need Autologous Stem Cell Transplantation (ASCT) in the Era of High-Dose Ara-C (HiDAC) and Rituximab Maintenance ?

Blood (2024) 144 (Supplement 1): 4422.

https://doi.org/10.1182/blood-2024-211078

Published: 2024

Journal Articles

Evolution of Treatment Patterns and Sequencing in Mantle Cell Lymphoma (MCL) in Spain and Their Impact on Survival. the Geltamo-MCL-2022 Study

Blood (2024) 144 (Supplement 1): 4403.

https://doi.org/10.1182/blood-2024-209936

Published: 2024

Journal Articles

Immunotherapy May be Preferable to Chemotherapy As Second-Line Treatment for POD24 Follicular Lymphoma (FL) Patients

Blood (2024) 144 (Supplement 1): 1658.

https://doi.org/10.1182/blood-2024-207871

Published: 2024

Journal Articles

Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD study

Blood (2024) 144 (9): 1001–1009.

https://doi.org/10.1182/blood.2023023525

Published: 2024

Includes: Supplemental data

Journal Articles

Impact of the Current Treatments on the Survival of Patients with Mantle Cell Lymphoma (MCL): A Real-Life Study on Behalf of the Spanish Group of Lymphoma (GELTAMO)

Blood (2023) 142 (Supplement 1): 1678.

https://doi.org/10.1182/blood-2023-186101

Published: 2023

Journal Articles

A Novel Machine-Learning Model to Predict Early Relapse in Mantle Cell Lymphoma (MCL)

Blood (2023) 142 (Supplement 1): 1675.

https://doi.org/10.1182/blood-2023-181628

Published: 2023

Journal Articles

Inherited Thrombocytopenias Predisposing to Hematologic Neoplasms. Experience of the Spanish Group for Inherited Platelet Disorders (GEAPC)

Blood (2023) 142 (Supplement 1): 1357.

https://doi.org/10.1182/blood-2023-180690

Published: 2023

Journal Articles

Beyond MIPI: Harnessing Machine Learning and Histological Subtype for Enhanced MCL Prognostication of Survival

Blood (2023) 142 (Supplement 1): 4419.

https://doi.org/10.1182/blood-2023-179174

Published: 2023

Journal Articles

Induction and Maintenance Therapy in Elderly Patients with Mantle Cell Lymphoma: Double-Randomized MCL R2 Elderly Clinical Trial By the European Mantle Cell Lymphoma Network

Blood (2023) 142 (Supplement 1): 979.

https://doi.org/10.1182/blood-2023-188788

Published: 2023

Journal Articles

Novel Agents May be Preferable to Standard Chemotherapy in Second-Line for Early Relapsing Follicular Lymphoma (FL) Patients

Blood (2023) 142 (Supplement 1): 6168.

https://doi.org/10.1182/blood-2023-186019

Published: 2023

Journal Articles

Novel variants in GALE cause syndromic macrothrombocytopenia by disrupting glycosylation and thrombopoiesis

Ana Marín-Quílez, Christian Andrea Di Buduo, Lorena Díaz-Ajenjo, Vittorio Abbonante, Elena Vuelta, Paolo Maria Soprano, Cristina Miguel-García, Sandra Santos-Mínguez, Inmaculada Serramito-Gómez, Pedro Ruiz-Sala, María Jesús Peñarrubia, Emilia Pardal, Jesús María Hernández-Rivas, José Ramón González-Porras, Ignacio García-Tuñón, Rocío Benito, José Rivera, Alessandra Balduini, José María Bastida

Blood (2023) 141 (4): 406–421.

https://doi.org/10.1182/blood.2022016995

Published: 2023

Includes: Supplemental data

Journal Articles

Rituximab Maintenance (RM) after First-Line (1L) Treatment Is Associated with a Lower Risk of Early-POD in Patients with Mantle Cell Lymphoma (MCL)

Blood (2022) 140 (Supplement 1): 9335–9337.

https://doi.org/10.1182/blood-2022-163180

Published: 2022

Journal Articles

Impact of Coronavirus (COVID-19) Pandemic on Maintenance Therapy for Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL)

Angel Serna, Angela Sanchez, Laia Lopez, Juan-Manuel Sancho, Eva Gonzalez Barca, Alberto Lopez-Garcia, Raul Cordoba, Adolfo Jesús Sáez Marín, Ana Isabel Jiminez Ubieto, Ainara Ferrero, Tomas García, Alba Cabirta, M Moraima Jimenez, Lucia Martin, Marta Julia, Sabela Bobillo, Ana Marin-Niebla, Francesc Bosch, Pau Abrisqueta

Blood (2022) 140 (Supplement 1): 9350–9352.

https://doi.org/10.1182/blood-2022-165996

Published: 2022

Journal Articles

Identification By Longread Nanopore Sequencing of a Complex Structural Variant in ITGB3 with a Founder Effect Causing Glanzmann's Thrombasthenia in Two Unrelated Patients

Maria Luisa Lozano, Ana Zamora-Cánovas, Belen De La Morena-Barrio, Cristina Sierra, Christoph Male, Jose Padilla, Maria Eugenia de la Morena-Barrio, Veronica Palma-Barqueros, Ana Sánchez-Fuentes, Agustín Rodriguez-Alen, Ana Marín-Quílez, Nuria Revilla Calvo, Vicente Vicente, Jose Maria Bastida, Javier Corral, Jose Rivera Pozo

Blood (2022) 140 (Supplement 1): 2695–2696.

https://doi.org/10.1182/blood-2022-160181

Published: 2022

Journal Articles

Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse

Blood (2022) 140 (17): 1907–1916.

https://doi.org/10.1182/blood.2022015560

Published: 2022

Includes: Supplemental data

Journal Articles

Rituximab-Lenalidomide(R2) Maintenance Is Superior to Rituximab Maintenance after First Line Immunochemotherapy in Mantle Cell Lymphoma: Results of the MCL R2 Elderly Clinical Trial

Blood (2021) 138 (Supplement 1): 379.

https://doi.org/10.1182/blood-2021-149600

Published: 2021

Journal Articles

Identification By Whole Exome Sequencing of the Molecular Defect in a Novel Gene Related to Glycosylation in Two Unrelated Families with Syndromic Macrothrombocytopenia

Ana Marín-Quílez, Elena Vuelta, Sandra Santos-Mínguez, Cristina Miguel-García, Pedro Ruíz-Sala, Veronica Palma-Barqueros, Lorena Díaz-Ajenjo, Inmaculada Serramito-Gómez, Maria Jesús Peñarrubia, Emilia Pardal, Daisy Castiñeiras-Ramos, José Ramón González-Porras, Jose Rivera, Rocio Benito, Jesus Maria Hernández-Rivas, Ignacio García-Tuñón, Jose Maria Bastida

Blood (2021) 138 (Supplement 1): 588.

https://doi.org/10.1182/blood-2021-150765

Published: 2021

Journal Articles

Final Results from a Phase 2 Study of Tipifarnib in Subjects with Relapsed or Refractory Peripheral T-Cell Lymphoma

Thomas E. Witzig, Lubomir Sokol, Won Seog Kim, Fátima de la Cruz Vicente, Dolores Caballero, Ranjana Advani, Raquel de Oña, Ana Marin Niebla, María José Terol, Domingo Domenech Eva, Nawal Bendris, Julie Mackey Ahsan, Mollie Leoni, Francine M. Foss

Blood (2021) 138 (Supplement 1): 621.

https://doi.org/10.1182/blood-2021-147279

Published: 2021

Journal Articles

Early Relapse after First Line Has a Significant Impact on Overall Survival in Patients with Mantle Cell Lymphoma (MCL)

Alba Cabirta, Pau Abrisqueta, Carla Sanchez-Ruiz, Sabela Bobillo, Cecilia Carpio, Gloria Iacoboni, Mercedes Gironella Mesa, Marta Julia, Angel Serna, Carlos Palacio, Josep Castellvi, Francesc Bosch, Ana Marin-Niebla

Blood (2021) 138 (Supplement 1): 1357.

https://doi.org/10.1182/blood-2021-150400

Published: 2021

Journal Articles

Prognostic Impact of Metabolic Tumor Burden in Large B-Cell Lymphoma Patients Receiving CAR T-Cell Therapy

Gloria Iacoboni, MD, Marc Simo, MD, Guillermo Villacampa, Eva Catala, Cecilia Carpio, MD, Candido Diaz-Lagares, MD, Angela Vidal-Jordana, MD, Sabela Bobillo, MD, Ana Marin-Niebla, MD PhD, Ana Perez, MD, Moraima Jiménez, Pau Abrisqueta, MD PhD, David Valcárcel, MD PhD, Francesc Bosch, MD PhD, Pere Barba, MD PhD

Blood (2020) 136 (Supplement 1): 27–29.

https://doi.org/10.1182/blood-2020-141777

Published: 2020

NARROW

Use of Post-Induction Treatment in Mantle Cell Lymphoma (MCL) in Spain. Do All Young Fit Patients Need Autologous Stem Cell Transplantation (ASCT) in the Era of High-Dose Ara-C (HiDAC) and Rituximab Maintenance ?

Evolution of Treatment Patterns and Sequencing in Mantle Cell Lymphoma (MCL) in Spain and Their Impact on Survival. the Geltamo-MCL-2022 Study

Immunotherapy May be Preferable to Chemotherapy As Second-Line Treatment for POD24 Follicular Lymphoma (FL) Patients

Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD study

Impact of the Current Treatments on the Survival of Patients with Mantle Cell Lymphoma (MCL): A Real-Life Study on Behalf of the Spanish Group of Lymphoma (GELTAMO)

A Novel Machine-Learning Model to Predict Early Relapse in Mantle Cell Lymphoma (MCL)

Inherited Thrombocytopenias Predisposing to Hematologic Neoplasms. Experience of the Spanish Group for Inherited Platelet Disorders (GEAPC)

Beyond MIPI: Harnessing Machine Learning and Histological Subtype for Enhanced MCL Prognostication of Survival

Induction and Maintenance Therapy in Elderly Patients with Mantle Cell Lymphoma: Double-Randomized MCL R2 Elderly Clinical Trial By the European Mantle Cell Lymphoma Network

Novel Agents May be Preferable to Standard Chemotherapy in Second-Line for Early Relapsing Follicular Lymphoma (FL) Patients

Novel variants in GALE cause syndromic macrothrombocytopenia by disrupting glycosylation and thrombopoiesis

Rituximab Maintenance (RM) after First-Line (1L) Treatment Is Associated with a Lower Risk of Early-POD in Patients with Mantle Cell Lymphoma (MCL)

Impact of Coronavirus (COVID-19) Pandemic on Maintenance Therapy for Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL)

Identification By Longread Nanopore Sequencing of a Complex Structural Variant in ITGB3 with a Founder Effect Causing Glanzmann's Thrombasthenia in Two Unrelated Patients

Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse

Rituximab-Lenalidomide(R2) Maintenance Is Superior to Rituximab Maintenance after First Line Immunochemotherapy in Mantle Cell Lymphoma: Results of the MCL R2 Elderly Clinical Trial

Identification By Whole Exome Sequencing of the Molecular Defect in a Novel Gene Related to Glycosylation in Two Unrelated Families with Syndromic Macrothrombocytopenia

Final Results from a Phase 2 Study of Tipifarnib in Subjects with Relapsed or Refractory Peripheral T-Cell Lymphoma

Early Relapse after First Line Has a Significant Impact on Overall Survival in Patients with Mantle Cell Lymphoma (MCL)

Prognostic Impact of Metabolic Tumor Burden in Large B-Cell Lymphoma Patients Receiving CAR T-Cell Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only